Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

  title={Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies},
  author={V. Margaret Jackson and David A. Price and Philip Albert Groton Carpino},
  journal={Expert Opinion on Investigational Drugs},
  pages={1055 - 1066}
Introduction: The discovery of new antiobesity agents has attracted considerable interest over the past decade, but many of the investigational agents that have advanced into human clinical trials have shown unacceptable adverse events and/or efficacy profiles. Areas covered: This review summarizes the available preclinical and clinical data of antiobesity drugs currently in Phase II clinical trials. It also provides a brief summary of the mechanisms underlying the regulation of energy… 
Latest approaches for the treatment of obesity
The application of monogenic forms of rare obesity and genome-wide association studies in selecting critical pathways for drug discovery and several pathways and pharmacological targets in the central nervous system that play an important role in the regulation of feeding behavior and energy homeostasis are described.
Horizons in the Pharmacotherapy of Obesity
  • J. R. Arch
  • Medicine, Biology
    Current Obesity Reports
  • 2015
New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue.
New perspectives on the development of antiobesity drugs.
This review deals with the positive results and the pitfalls obtained following holistic approaches to obesity, with a view on their clinical trial studies.
Obesity: Current and potential pharmacotherapeutics and targets
Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
This review will outline the mechanisms of action of these newer generation weight management medications and their implications for both diabetes and cardiovascular risks.
Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008-2014).
A review of theMC4R patent landscape from 2008 to 2014 is provided and the physicochemical properties of compounds described herein are analyzed to avoid some of the undesirable side effects associated with MC4R activation.
The current progress of the anti-obesity potential of natural flavonoids and their various mechanisms that target multiple molecular for preventing the cluster of diseases are summarized.
Application of Network Pharmacology to Elucidate The Potential Mechanism of Finger Citron Against Obesity
This study provides insights into the potential mechanism of FS in ameliorating obesity after screening for associated key target genes and signaling pathways and molecular docking analysis showed that the main ingredients were tightly bound to the core targets, further confirming the effects of weight loss.
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
  • Tushar Madaan, M. Akhtar, A. Najmi
  • Medicine, Biology
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2016


A review of late-stage CNS drug candidates for the treatment of obesity
The therapeutic approaches to tackle obesity that are in late-stage clinical development are described and some approaches have already demonstrated an ability to deliver levels of efficacy that are not achievable with the current antiobesity drug therapies.
Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
New insights have been made into the physiologic regulation of energy balance and the subordinate central and peripheral circuits coordinating appetite, metabolism, and lipogenesis which has revealed previously unrecognized molecular targets for controlling appetite and managing weight, and emerged a new wave of targeted pharmacotherapies to prevent and control obesity.
Novel strategy for the use of leptin for obesity therapy
Combination pharmacological therapy, such as pramlintide/metreleptin, for the treatment of obesity is very promising and is supported by encouraging weight loss results and improvement in metabolic makers in early-phase clinical studies.
Current and Future Drug Targets in Weight Management
This review provides an overview of the different molecular strategies intended to lower body weight or adipose tissue mass and identifies several other potentially promising compounds and combinations currently undergoing phase II and III testing.
Long-term drug treatment for obesity: a systematic and clinical review.
A systematic review of medications currently approved in the United States for obesity treatment in adults found that medications approved for long-term obesity treatment, when used as an adjunct to lifestyle intervention, lead to greater mean weight loss and an increased likelihood of achieving clinically meaningful 1-year weight loss relative to placebo.
Consensus development conference on antipsychotic drugs and obesity and diabetes.
A consensus position is developed on the relationship between the second-generation antipsychotics (SGAs) and the development of major CVD risk factors, including obesity, diabetes, and dyslipidemia.
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
Targeting the molecular pathways that mediate the beneficial effects of calorie restriction and exercise may represent an alternative therapeutic approach for the treatment of chronic metabolic disorders such as obesity.
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
The safety and efficacy of currently approved drug therapies have not been evaluated in children and elderly patient populations and there is limited information in adolescents, whilst the long-term safety of current and potential new drug therapies in adults will require several years of postmarketing surveillance to fully elucidate their adverse effect profiles.
Evaluation of efficacy and safety of orlistat in obese patients
Orlistat is an effective and well-tolerated antiobesity drug, which can be employed as an adjunct to therapeutic lifestyle changes to achieve and maintain optimal weight.
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
  • Jin-Hee Shin, K. Gadde
  • Medicine, Psychology
    Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2013
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine